Home » Stocks » MNTA

Momenta Pharmaceuticals, Inc. (MNTA)

Sep 30, 2020 - MNTA was delisted after being acquired by JNJ
Stock Price: $52.48 USD 0.00 (0.00%)
Updated Oct 1, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap 6.24B
Revenue (ttm) 30.07M
Net Income (ttm) -227.83M
Shares Out 118.97M
EPS (ttm) -2.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 1, 2020
Last Price $52.48
Previous Close $52.48
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 52.46 - 52.53
Day's Volume 0
52-Week Range 12.21 - 52.53

More Stats

Market Cap 6.24B
Enterprise Value 5.81B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 118.97M
Float 117.84M
EPS (basic) -2.13
EPS (diluted) -2.09
FCF / Share -1.71
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.41M
Short Ratio 0.79
Short % of Float 4.59%
Beta 1.79
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 207.61
PB Ratio 15.79
Revenue 30.07M
Operating Income -245.14M
Net Income -227.83M
Free Cash Flow -200.94M
Net Cash 438.15M
Net Cash / Share 3.68
Gross Margin -245.26%
Operating Margin -815.18%
Profit Margin -757.60%
FCF Margin -668.20%
ROA -30.56%
ROE -64.36%
ROIC -98.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (9)

Buy 1
Overweight 0
Hold 8
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$51.00*
(-2.82% downside)
Low
40.0
Current: $52.48
High
53.0
Target: 51.00
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue23.8775.5913911089.6552.2535.4763.92283117
Revenue Growth-68.42%-45.57%26.7%22.27%71.58%47.33%-44.52%-77.42%142.41%-
Gross Profit23.8775.5913911089.6552.2535.4763.92283117
Operating Income-312-181-92.55-74.73-84.43-99.40-110-60.1118036.47
Net Income-290-176-88.10-21.00-83.31-98.60-108-58.6518037.29
Shares Outstanding99.3477.8573.1468.6663.1351.6650.9150.4149.8544.63
Earnings Per Share-2.92-2.26-1.20-0.31-1.32-1.91-2.13-1.163.550.81
EPS Growth--------338.27%-
Operating Cash Flow-205-156-29.098.99-71.52-65.17-86.839.00214-1.06
Capital Expenditures1.37-7.57-16.86-5.61-4.07-8.36-9.45-15.49-15.36-1.67
Free Cash Flow-203-163-45.953.38-75.58-73.53-96.28-6.49198-2.73
Cash & Equivalents523460366375371212266361366155
Total Debt---------1.99
Net Cash / Debt523460366375371212266361366153
Assets618532459478421256317407421228
Liabilities16470.5685.2810651.0649.8546.9846.1417.8321.47
Book Value454461374372370206270360403206
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Momenta Pharmaceuticals, Inc.
Country United States
Employees 118
CEO Craig A. Wheeler

Stock Information

Ticker Symbol MNTA
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: MNTA
IPO Date June 22, 2004

Description

Momenta Pharmaceuticals, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.